Tag: adamas pharmaceuticals

December 9, 2020

3 Alzheimer’s Disease Treatment Stocks on the NASDAQ

The Alzheimer's disease treatment market is projected to reach US$12.9 billion by 2028. Which stocks should be on investors' radar?
January 2, 2020

Adamas Announces Settlement of Patent Litigation with Sandoz

Adamas has entered into a settlement agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s new drug application.
September 20, 2019

Adamas Announces Data for GOCOVRI in Parkinson’s Disease

Adamas Pharmaceuticals (NASDAQ:ADMS) has announced presentation of new data on GOCOVRI to treat dyskinesia in patients with Parkinson’s disease. As...
December 19, 2018

Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new...
October 4, 2018

Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled...